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ABSTRACT
Introduction. Hyponatremia complicates cirrhosis and predicts short term mortality, including adverse outcomes before and after liver transplantation. Material and methods. From April 1, 2008, through April 2,
2010, all adult candidates for primary liver transplantation with cirrhosis, listed in Region 11 with hyponatremia, were eligible for sodium (Na) exception. Results. Patients with serum sodium (SNa) less than 130
mg/dL, measured two weeks apart and within 30 days of Model for End Stage Liver Disease (MELD) exception request, were given preapproved Na exception. MELD Na was calculated [MELD + 1.59 (135-SNa/30
days)]. MELD Na was capped at 22, and subject to standard adult recertification schedule. On data end of
follow-up, December 28, 2010, 15,285 potential U.S. liver recipients met the inclusion criteria of true MELD
between 6 and 22. In Region 11, 1,198 of total eligible liver recipients were listed. Sixty-two (5.2%) patients
were eligible for Na exception (MELD Na); 823 patients (68.7%) were listed with standard MELD (SMELD); and
313 patients (26.1%) received HCC MELD exception. Ninety percent of MELD Na patients and 97% of HCC
MELD patients were transplanted at end of follow up, compared to 49% of Region 11 standard MELD and
40% of U.S.A. standard MELD (USA MELD) patients (p < 0.001); with comparable dropout rates (6.5, 1.6, 6.9,
9% respectively; p = 0.2). MELD Na, HCC MELD, Region 11 SMELD, and USA MELD post-transplant six-month
actual patient survivals were similar (92.9, 92.8, 92.2, and 93.9 %, respectively). Conclusion. The Region 11
MELD Na exception prospective trial improved hyponatremic cirrhotic patient access to transplant equitably, and without compromising transplant efficacy.
Key words. Liver transplantation. Risk factors. Organ allocation. Resource utilization. Wait list mortality.

INTRODUCTION
In 2002 in the United States, the Model for EndStage Liver Disease (MELD) score became the standard for determining liver allocation for

Correspondence and reprint request: Robert A. Fisher M.D., FACS
Hume Lee Professor of Surgery and Pediatrics
Director, Liver Transplant Program
Virginia Commonwealth University
PO Box 980254. Richmond, Virginia 23298-0254
Phone: (804) 828-2461
Fax: (804) 828-2462
E mail: rafisher@vcu.edu
Web site: rafisher.vcu.edu
Manuscript received: August 02, 2011.
Manuscript accepted: October 03, 2011.

transplantation.1 MELD was practical and quickly
validated at a national level by its transparent and
collegial development; and because it relied on three
objective and reproducible, laboratory tests that
were considered routine.2,3 Serum sodium (SNa) was
not part of the original MELD calculation. Numerous high quality studies in patients with cirrhosis
have demonstrated that hyponatremia can predict
short-term mortality independently of other predictors, including MELD score.4-13 Furthermore, using
United States’ data derived from all adult candidates for first-time liver transplant, registered with
the Organ Procurement and Transplant Network
(OPTN) in 2005 and 2006, the assignment of transplant priority using MELD score combined with
serum sodium could have prevented death on the
waiting list in 32 patients out of a total 477 patients

© 2019, Fundación Clínica Médica Sur, A.C. Published by Elsevier España S.L.U. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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(7%) whom died within 3 months of transplant waiting list registration.14 In this study, the Region 11
(R11) Liver Program Directors developed a prospective MELD Na exception study, with United Network of Organ Sharing (UNOS) approval and
Region 11 prospective oversight. The main objective
was to determine whether a MELD Na exception
would improve access to transplant for these highrisk hyponatremic and cirrhotic patients without
unfairly disenfranchising other transplant eligible
patient groups.

MATERIAL AND METHODS
From April 1, 2008 through April 2, 2010, patients listed for transplant in Region 11 with hyponatremia were eligible for a Sodium Exception.
Patients with two serum sodium (Na) of 130 meq/L
or less, at least two weeks but less than thirty days
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apart, were granted approval for the Sodium Exception. MELD Na was calculated as follows:4
[MELD + 1.59 (135- serum NA/30 days)]
MELD Na score was capped at 22 and ascites was
not graded. Re-certification followed the UNOS
Adult Liver Candidate Reassessment and Recertification Rules: A MELD Score d 24 but > 18 requires
recertification every month with laboratory values
of the patient no older than seven days. Patients
from all other regions continued to be listed per
UNOS policy regardless of serum sodium values.
On December 28, 2010, data for this analysis was
obtained from UNOS and analyzed by the unbiased
statistician co authors (AM H and MKB). All patients had a minimum of six months of follow up
from time of listing. Univariate comparisons were
performed using F2 test of proportions or t-test, as

Table 1. Demographic characteristics of each group.
R11 Na excp.

R11 HCC

R11 Std MELD

USA Std MELD

p-value

(n = 62)

excp R11 (n = 313)

(n = 823)

(n = 13,212)

(4-sample ANOVA)

Age

53.7 ± 8.6

54.8 ± 12.1

52.1 ± 11.7

51.9 ± 14.3

0.003

(mean yrs)

(52.6, 54.8)

(54.1, 55.5)

(51.7, 52.5)

(51.8, 52.0)

(A & B > C & D)

A. American
(%)

4 (6.5%)
(1.8, 15.7)

34 (10.9%)
(7.6, 14.8)

104 (12.6%)
(10.4, 15.1)

1,097 (8.3%)
(7.8, 8.7)

0.0002
C>D

Male
(%)

38 (61.3%)
(48.0, 73.4)

234 (74.7%)
(69.6, 79.5)

541 (65.7%)
(62.4, 69.0)

8,535 (64.6%)
(63.5, 65.4)

0.002
B>C&D

Transplanted

56 (90%)
(80.1, 96.4)

303 (97%)
(94.2, 98.5)

403 (49%)
(45.5, 52.4)

5,319 (40%)
(39.4, 41.1)

< 0.0001
A&B>C>D

Died/Too sick

4 (6.5%)
[1.8, 15.7]

5 (1.6%)
[0.5, 3.7]

57 (6.9%)
[5.3, 8.9]

1,195 (9.0%)
[8.6, 9.5]

< 0.0001
B<C&D

Still listed

1 (1.6%)
[<0.01, 8.7]

3 (1.0%)
[0.1, 2.8]

311 (37.8%)
[34.5, 41.2]

5,606 (42.4%)
[41.6, 43.3]

< 0.0001
A&B<C<D

Time to Tx
(Mean days)
DD only

111.7 ± 120
(96.3, 127.1)

66.5 ± 97.8
(61.0, 72.0)

121.1 ± 130.4
(116.5, 125.7)

133.4 ± 139.6
(132.2, 134.6)

< 0.0001
B < A, C, D
A, C < D

Na at time of Tx

129.5 ± 4.5
(128.9, 130.1)

137.3 ± 3.7
(136.8, 137.5)

136.0 ± 4.4
(135.8, 136.2)

136.6 ± 4.8
(136.56, 136.64)

< 0.0001
A < B, C, D

Patient survival
(180 day)

92.90%

92.80%

92.20%

93.90%

NS

A

B

C

D

List Outcomes:

R11: region 11. Na: sodium. HCC: hepatocellular carcinoma. Std: standard. MELD: Model for End Stage Liver Disease. USA: United States of America.
A. American-African American. Tx: transplant. DD: deceased donor. N/S: not significant.
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appropriate. Kaplan-Meier post-transplant patient
survival curves were constructed and compared with
a log-rank test. For table 1, 95% confidence intervals, were constructed from the student’s t distribution for continuous variables and from the binomial
distribution for categorical variables. Four sample
comparisons were evaluated using analysis of variance (ANOVA) for continuous variables and F2
test for contingency tables for categorical variables.

RESULTS
Between April 1, 2008 and April 2, 2010, a total of
22,677 patients were listed for liver transplant. Of
these, 15,285 patients met the inclusion criteria of
true MELD between 6 and 22. Demographic characteristics of the patients are shown in table 1. In Region 11, 1,198 patients were listed. Of those,
sixty-two (5.2%) patients were eligible for Sodium
Exception, (MELD Na), 313 (26.1%) patients for
HCC exception (HCC MELD), and 823 (68.7%) were
assigned standard MELD (SMELD). Over the same
time period, 13,212 patients were included from the
other regions (USA MELD). Age at listing, proportion of African-Americans, and proportion of males
were not different between groups. The Region 11
exception groups were transplanted faster than both
the SMELD and USA MELD groups: 90% of MELD

Figure 1. Post-transplant patient survival. Std M/P: standard
MELD/patients (Pts) in region 11. Non 11-standard MELD/Pts
in the USA. HCC Exc: hepatocellular carcinoma MELD exception/Pts in region 11. Na Exc: Sodium MELD exception/Pts in
Region 11. Status 1: designation to acute liver failure Pts and
hepatic artery thrombosis post liver transplant Pts given
highest organ availability in Region 11. * Status 1 Pts survival
at 6months: 74.6% (p = 0.03 < 4 other Pt groups).

, 2012; 11 (1): 62-67

Na and 97% of HCC MELD patients received a
transplant by the end of the follow up period compared to 49% of SMELD and 40% of USA MELD (p <
0.0010), with comparable dropout rates (6.5, 1.6,
6.9, and 9%, respectively, p = 0.2). Mean wait times
were 111 days for the MELD Na group, 66 days for
the HCC MELD group, 121 days for the SMELD
group and 133 days for the USA MELD group (p <
0.001). Six-month post-transplant patient survival is
shown in figure 1, with Status 1 patient-survival
shown for comparison. MELD Na, HCC MELD,
SMELD, and USA MELD groups had comparable 6month survival (92.9, 92.8, 92.2, and 93.9%, respectively), while 6-month survival in the Status 1
patients was only 74.6% (p = 0.03).

DISCUSSION
Prior to 2002, HCC patients were sometimes unnecessarily prioritized, which disenfranchised nonHCC patients with equivalent mortality risk on the
waiting list. Establishment of objective criteria for
awarding MELD exception points was successful in
the HCC population. There existed considerable evidence that an objective, reliable, and routinely available serum Na test could help better determine
mortality risk in cirrhotic patients on the transplant list with equal MELD scores. Single center
studies, including our own in a US veteran population, showed that a serum Na of < 135 meq/L was
the single most important variable, in multivariable
analysis, with significant predictive value for 180
day mortality in 12% of the cirrhotic population
with MELD scores < 21.6,7 Although the majority of
patients removed from the United Network for Organ Sharing/Organ Procurement and Transplantation Network waiting list for death or being too sick
have high MELD scores, the addition of serum Na
would benefit the most at risk for death waiting list
population underserved by MELD.15
In 2005, and 2006, at the VCU Health Center, the
waiting list mortality of 16% (22 patients) and 14%
(16 patients) respectively, consisted of one half late
referred high MELD liver failure patients and one
half low MELD patients (MELD 14 to 21). We reasoned that patients we were caring for already with
low MELD who could be more accurately risk stratified on the waiting list could be benefited with
greater probability by affecting allocation policy
compared to changing the complex variables involved in late referral patients not in our direct care.4-7
The desire to prevent inequity to the deserving
listed 15 to 21 MELD population due to overcompen-
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sation to serve a few underserved low MELD patients resulted in the present study; a prospective
MELD Na study exception protocol created over 1
year, 2007, of quarterly Region 11 Liver Program
Director study development. The first model required a single serum Na of less than 135 meq/L and
capped the MELD score at 26 with graded ascites.
After three iterations, the present study protocol
was accepted and implemented. This study had
UNOS approval, automation of patient listing, data
retrieval with quarterly safety oversight, and study
initiation on April 1, 2008. The study design included two senior statisticians with transplant expertise who where tasked with performing quarterly
analyses as agreed to by all Principle Investigators.
The stop study date decision was to be determined
by these two senior analysts (A.M.H. and M.K.B) in
concert with the Principle Lead Investigator (R.A.F)
once it was concluded that the three principle study
aims could be answered conclusively by the study
cohort:
• Would the volume of MELD Na exception patients approximate 7 to 8% predicted compared to
non-Exception MELD d 22, and other MELD exception patients?
• What wait list outcomes (transplantation; died/
inactivated; still waiting) could be anticipated in
MELD Na exception patients and MELD equivalent non exception patients, due to the study design?
• What effect would MELD Na exception study
have on post transplant patient groups survival?
The 11 UNOS regions vary not only in access to
liver transplantation and end stage liver disease population event rates, but also in peer review liver
allocation practice.16-18 An important issue addressed by this study is the number of patients who
might be affected by nation-wide implementation of
a Na MELD exception. Over the 2 years of prospective study in Region 11, of the 885 patients listed
(excluding HCC exceptions), 62 patients (7%) were
listed with the MELD Na exception. This 7% figure
mirrors our original affected estimated population
prediction and exactly that of a previous study that
estimated that 7% of deaths on the wait list could
have been avoided with the implementation of
MELD exception for hyponatremia.14 This supports
our hope that we have developed an effective MELD
allocation modification that appropriately prioritizes
those patients on the wait list underserved by a
MELD score that underestimated this group of pa-
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tients’ risk of death without harming their “less
sick” equal MELD “neighbors”. Our original estimate of 7% MELD Na exception patients out of the
total Region 11 MELD d 22 listed patients to study,
correctly influenced the study to not randomize
MELD Na exception patients to receive the 22
points or to receive no Na calculated MELD points.
This direct comparison study would have required
more than 5 years of study. Instead, by giving all
hyponatremic patients (Na d 130) the MELD exception and demonstrating a drop in wait list mortality
for the exception and the standard MELD group below the 14 to 16% wait list mortality in Region 11
centers, we could show indirect evidence that MELD
Na was effective.
It is important to note that, as shown in table 1,
the Region 11 MELD Na exception modification did
not significantly, negatively impact the wait list
mortality rate for the other groups of transplantation eligible patients. The mortality rate for the
HCC MELD and SMELD groups in Region 11 were
equivalent to national rates where no MELD Na
was being made. The MELD Na group saw a 90%
transplant rate, which is still less than that of the
HCC MELD group (97%), but, as hoped, significantly higher than the rate seen in either the SMELD
group (49%) or the USA MELD group (40%) (p <
0.001) (Table 1).
At the outset of the study there were concerns
that the MELD Na exception would mean that hyponatremic patients would be transplanted ahead of
patients with HCC. Our study indicates that, not
only were HCC patients still transplanted at the highest rate, but that HCC MELD patients were transplanted with a significantly shorter wait list time of
66 days as compared to 111 days for MELD Na pts,
121 days for SMELD patients, and 133 days for
USA MELD patients (p < 0.001). The wait list mortality for standard Region 11 MELD patients (6.9%)
was no different that the wait list mortality for Region 11 MELD Na patients (6.5%) or wait list mortality for USA standard MELD patients (9.0%).
More importantly, of the 1,395 patients dying or removed from the wait list of USA standard MELD
patients, 202 patients (16.9%) had Na d 130 and a
MELD score < 21 that could be salvaged by a
National MELD Na policy with no increase risk of
death to USA MELD patients who do not qualify for
exception points.
To allay fears among some Program Directors
that the serum Na would be manipulated to advantage some patients, our exception required that the
serum Na be measured twice with at least two weeks
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separating the measurements and that both measurements demonstrated a serum Na < 130 meq/L.
These requirements may be more conservative than
necessary considering that there is an extensive
body of literature that supports the idea that a
serum Na < 135 meq/L predicts a more advance
stage of cirrhosis, more significantly portal hypertension, more impaired body-water homeostasis,
more profound liver dysfunction and a significant
increased risk of death. 4,7,19-23 While our requirements may have been overly conservative, they did
result in a MELD Na group with very significantly
depressed serum Na at the time of transplant as
compared to the other groups (p < 0.001) that indeed were the true at risk underserved group by native MELD.
Previous literature suggests that hyponatremia
pre-transplant is associated with significant morbidity, but not significant mortality, post transplant.24,25 Our prospective study did not study post
transplant morbidity and found that the 6-month
post transplant patient survival, at 92.9%, was not
significantly different than any of the other groups
(Table 1). We can conclude then, that the MELD Na
exception did not reduce, transplant efficacy as measured by patient survival.
The Region 11 MELD Na exception as examined
in this study was subsequently adopted, in 2011, as
standard allocation practice by the Region 11 Liver
Program Directors. Previous work in Region 11 studying ascites and hyponatremia in 211 Veterans
with cirrhosis, suggested that patients with ascites
on abdominal ultrasound may be incrementally disadvantaged in their access to transplantation when
the laboratory MELD score is < 21.7 This finding
was recently validated in a study of 18,124 US subjects listed for liver transplantation.26 Concerns regarding the objectivity of quantifying ascites were
behind the decision to eliminate ascites from the present MELD Na exception. Future work may include
investigations into the clinical relevance and impact
of adjusting the MELD Na exception for the presence or absence of ascites.
This Region 11 cooperative, prospective MELD
Na exception model took one year to plan and obtain a consensus study; two years to conduct; and is
the first true multi-center test of the equity and efficacy of a MELD adjustment for hyponatremia at a
Regional level, and may be viewed as a preliminary
step to national implementation. Our results demonstrate that the MELD Na exception allows for a
high rate of transplant for that patient group with
excellent survival.

, 2012; 11 (1): 62-67

ABBREVIATIONS
Region 11 UNOS organ allocation region made up
of states of Kentucky, North Carolina, South Carolina, Tennessee, Virginia.
• MELD: Model of End-Stage Liver Disease score.
• MELD Na: Model for End-Stage Liver Disease
+ serum Na score.
• SNa: serum sodium.
• OLTX: adult orthotopic liver transplant.
• OPTN: Organ Procurement Transplant
Network.
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